Date: Sunday, June 2, 2019
Session Name: Concurrent Session: B-cell / Antibody /Autoimmunity
Session Time: 4:30pm-6:00pm
Presentation Time: 4:30pm-4:42pm
Location: Room 310
*Purpose: B-cell activating factor (BAFF) is a cytokine that plays a role in the survival, proliferation and differentiation of B-cells. The aim of this study is to develop an allosensitized mouse model using HLA.A2 transgenic mice, and to observe the effects of anti-BAFF monoclonal antibody (mAb) in this model.
*Methods: Wild-type C57BL/6 mice were sensitized with skin allografts from C57BL/6-Tg (HLA-A2.1)1Enge/J mice and were treated with intraperitoneal injections of anti-BAFF mAb (named Sandy-2) or control IgG1 antibody. Donor specific antibody (DSA) responses were observed by measuring anti-HLA.A2 antibodies in serum of the mice using the luminex assay. B-cell fractions in mice bone marrow and spleen were determined using flow cytometric analysis, and mRNA profiling was done using microarray analysis.
*Results: HLA.A2-specific IgG was reduced in mice injected with anti-BAFF mAb compared to the control group (Δ-15.8±6.7 vs.Δ42.2±64.7, p = 0.1). BAFF blockade resulted in increased pre-pro and immature B-cell proportions in the bone marrow and decreased mature B-cells (p<0.05 vs. control). In the spleen as well, an increase in the proportion of transitional B-cells was observed with a significant decrease in marginal and follicular B-cells (p<0.05 vs. control). There was no significant difference in proportions of long lived plasma cells in the bone marrow and memory B-cells in the spleen. Microarray analysis results showed that, 19 genes were significantly up (>2 fold, p<0.05) or down regulated (<2 fold, p<0.05) in the BAFF blockade group. On further analysis using the CIBERSORT method, gene set enrichment results showed that the IL12 pathway, NO-IL12 pathway and CSK pathways were most significantly enriched (Nominal p-value <0.05, FDR <25%) in the BAFF blockade group.
*Conclusions: Anti-BAFF monoclonal antibody inhibited anti-HLA.A2 responses resulting in reduction of HLA.A2-specific IgG and significantly inhibited differentiation and maturation of B cells in both the bone marrow and spleen. Our data suggests that BAFF suppression may serve as a useful target in desensitization therapy.
To cite this abstract in AMA style:Min J, Lee H, Kim B, Park K, Doh K, Kim T, Yoon H, Yang C, Oh E, Chung B. The Effects of Anti-BAFF Monoclonal Antibody in the HLA-A2 Sensitized Mouse Model [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/the-effects-of-anti-baff-monoclonal-antibody-in-the-hla-a2-sensitized-mouse-model/. Accessed December 5, 2019.
« Back to 2019 American Transplant Congress